Ranbaxy fights on as Teva's generic Nexium hits US
This article was originally published in Scrip
Executive Summary
The US FDA has approved the first generic version of AstraZeneca's Nexium (esomeprazole magnesium delayed-release capsules) from Teva arm Ivax Pharmaceuticals, confirming Ranbaxy's fears that it had forfeited its 180-day exclusivity for the 20mg and 40mg versions of the product.
You may also be interested in...
Cipla First On Generic Nexium Formulation
India’s Cipla has received the first US approval for a generic rival to Nexium delayed-release oral suspension in the US. The firm recently declared its intention to direct funds to more complex formulations in the US but nevertheless continues to grow its vast portfolio in the market.
Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Tripartite Avigan Alliance Aims For Global Access
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.
Need a specific report? 1000+ reports available
Buy Reports